BAISHIDENG PUBLISHING GROUP INC
8226 Regency Drive, Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242 Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com http://www.wjgnet.com

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastrointestinal Oncology
ESPS manuscript NO: 19260
Title: Genomic alterations in pancreatic cancer and their relevance to therapy
Reviewer's code: 00069406
Reviewer's country: China
Science editor: Yue-Li Tian
Date sent for review: 2015-05-08 16:22
Date reviewed: 2015-05-18 11:20

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
[ ] Grade A: Excellent	[ ] Grade A: Priority publishing	Google Search:	[ ] Accept
[ ] Grade B: Very good	[Y] Grade B: Minor language polishing	[ ] The same title	[ ] High priority for publication
[ ] Grade C: Good	[ ] Grade C: A great deal of language polishing	[ ] Duplicate publication	[Y] Rejection
[Y] Grade D: Fair	[ ] Grade D: Rejected	[ ] Plagiarism	[ ] Minor revision
[ ] Grade E: Poor		[Y] No	[ ] Major revision
		BPG Search:	
		[ ] The same title	
		[ ] Duplicate publication	
		[ ] Plagiarism	
		[Y] No	

COMMENTS TO AUTHORS

The current review conclude the recent progress on genomic alterations in pancreatic cancer and their relevance to therapy. However, there was less novelty in the text to warrant published. KRAS, CDKN2A, TP53 and SMAD4 are the four genes frequently mutated in PDAC, which are already known for years. Also, there is no more pregresses to be concluded on target therapy for PDAC. So the significance of review is fair. Figure 1 contains less information than which is already published in the literature.

BAISHIDENG PUBLISHING GROUP INC
8226 Regency Drive, Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242 Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com http://www.wjgnet.com

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastrointestinal Oncology
ESPS manuscript NO: 19260
Title: Genomic alterations in pancreatic cancer and their relevance to therapy
Reviewer's code: 00224612
Reviewer's country: Germany
Science editor: Yue-Li Tian
Date sent for review: 2015-05-08 16:22
Date reviewed: 2015-05-08 21:12

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
[ ] Grade A: Excellent	[Y] Grade A: Priority publishing	Google Search:	[ ] Accept
[Y] Grade B: Very good	[ ] Grade B: Minor language polishing	[ ] The same title	[ ] High priority for publication
[ ] Grade C: Good	[ ] Grade C: A great deal of language polishing	[ ] Duplicate publication	[ ] Rejection
[ ] Grade D: Fair	[ ] Grade D: Rejected	[ ] Plagiarism	[Y] Minor revision
[ ] Grade E: Poor		[Y] No	[ ] Major revision
		BPG Search:	
		[ ] The same title	
		[ ] Duplicate publication	
		[ ] Plagiarism	
		[Y] No	

COMMENTS TO AUTHORS

The manuscript by Takai and Yachida is a well written, up-to-date and in-depth review regarding genomic alterations in pancreatic cancer and their relevance to therapy. There are some minor comments/suggestions: The authors state that "although great efforts have been made to develop small-molecular inhibitors of mutant KRAS, no clinically effective antagonist has yet been identified". In this context, the authors should cite and include: The Ras renaissance. PMID: 25877186. The authors state that "activation of the PI3K/Akt/mTOR pathway also plays an important role in maintenance of pancreatic cancer". In this context, the authors might also want to cite and include: A subset of metastatic pancreatic ductal adenocarcinomas depends quantitatively on oncogenic Kras/Mek/Erk-induced hyperactive mTOR signalling. PMID: 25601637. The authors state that "interestingly, blockade of the Hedgehog pathway has also been proposed as a means to target the tumor stroma and improve delivery of gemcitabine in vivo". The authors should also state and cite that the Saridegib trial failed. Figure 1 should be omitted since the authors do not review in depth pancreatic cancer progression models. A table depicting the core signalling pathways and current trials/targets for each pathway would be helpful.